Androxal: Clinically Validated Testosterone Restoration Therapy
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per tab | Price | Buy |
| 30 | $1.58 | $47.30 (0%) | 🛒 Add to cart |
| 60 | $1.10 | $94.60 $66.22 (30%) | 🛒 Add to cart |
| 90 | $0.95
Best per tab | $141.90 $85.14 (40%) | 🛒 Add to cart |
Similar products
Androxal (enclomiphene citrate) represents a significant advancement in the treatment of male hypogonadism, specifically addressing secondary hypogonadism with a targeted, non-steroidal mechanism. This selective estrogen receptor modulator (SERM) works at the hypothalamic-pituitary level to stimulate the body’s own natural production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby promoting endogenous testosterone synthesis. Unlike exogenous testosterone replacement therapies (TRT), which can suppress spermatogenesis and lead to testicular atrophy, Androxal offers the dual benefit of elevating serum testosterone levels while maintaining or even improving semen parameters. It is indicated for adult males with demonstrated hypogonadism and offers a physiologically restorative approach to hormone balance.
Features
- Active Pharmaceutical Ingredient: Enclomiphene citrate (the trans-isomer of clomiphene)
- Mechanism of Action: Central (hypothalamic-pituitary) estrogen receptor antagonism
- Dosage Form: Oral tablet
- Standard Strengths: 12.5 mg and 25 mg tablets
- Prescription Status: Rx-only, Schedule IV controlled substance in some jurisdictions
- Bioavailability: High oral absorption, not significantly affected by food
- Half-life: Approximately 5-7 hours, supporting once-daily dosing
- Metabolism: Hepatic, primarily via CYP2D6 and CYP3A4
- Excretion: Primarily fecal (via bile), with minor renal excretion
Benefits
- Restores serum testosterone to eugonadal ranges through physiological stimulation of the hypothalamic-pituitary-gonadal (HPG) axis
- Preserves or improves testicular volume and spermatogenic function, making it suitable for men concerned about fertility
- Avoids the supraphysiological testosterone peaks and troughs associated with traditional TRT, potentially reducing cardiovascular and hematological risks
- Oral administration eliminates the need for injections, gels, or patches, improving convenience and adherence
- Demonstrates a favorable safety profile in clinical trials with low incidence of serious adverse events
- May improve symptoms of hypogonadism including low libido, fatigue, and depressed mood without suppressing endogenous hormone production
Common use
Androxal is primarily prescribed for the treatment of secondary hypogonadism (hypogonadotropic hypogonadism) in adult men. This condition is characterized by low testosterone production due to insufficient stimulation from the pituitary gland, rather than primary testicular failure. Common underlying causes include obesity, metabolic syndrome, opioid use, pituitary disorders, or idiopathic deficiencies. Patients typically present with symptoms such as decreased energy, reduced muscle mass, increased body fat, diminished libido, erectile dysfunction, and mood disturbances. Androxal is particularly valuable for men who wish to maintain fertility potential while treating their hypogonadal symptoms, as it stimulates both testosterone production and spermatogenesis simultaneously.
Dosage and direction
The recommended starting dose of Androxal is 12.5 mg administered orally once daily, preferably at the same time each day. Administration may occur with or without food. After 4-6 weeks of treatment, serum testosterone levels should be measured to assess response. If testosterone levels remain below the eugonadal range (typically 300-1000 ng/dL) and the medication is well-tolerated, the dose may be increased to 25 mg once daily. The maximum recommended daily dose is 25 mg. Treatment duration should be individualized based on therapeutic response and ongoing assessment of benefits versus risks. Regular monitoring of testosterone levels, complete blood count, lipid profile, and prostate-specific antigen (PSA) is recommended during treatment.
Precautions
Prior to initiating Androxal therapy, a comprehensive evaluation should confirm the diagnosis of secondary hypogonadism and exclude primary testicular failure. Baseline assessments should include measurement of total testosterone, LH, FSH, prolactin, and a complete metabolic panel. Patients with a history of pituitary tumors should undergo appropriate imaging before treatment. Regular ophthalmologic examinations are recommended during prolonged treatment due to potential visual disturbances associated with SERMs. Androxal should be used cautiously in patients with hepatic impairment, as metabolism occurs primarily in the liver. Patients should be monitored for changes in mood or behavior, including depression or suicidal ideation. Those with a history of thromboembolic disorders should be carefully evaluated before treatment initiation.
Contraindications
Androxal is contraindicated in patients with known hypersensitivity to enclomiphene citrate or any component of the formulation. It should not be used in men with primary testicular failure (hypergonadotropic hypogonadism), as the mechanism of action requires functional Leydig cells. Additional contraindications include pituitary tumors (except after appropriate treatment and stabilization), untreated prolactinomas, and pre-existing liver disease classified as Child-Pugh C. Androxal is not indicated for use in women and is absolutely contraindicated during pregnancy due to potential fetal harm. Concurrent use with other SERMs or estrogen-containing products is not recommended.
Possible side effect
The most commonly reported adverse reactions in clinical trials (>5% incidence) include headache, nausea, dizziness, and injection site reactions (though administered orally, some studies used injectable formulations in trials). Less frequent side effects may include visual disturbances (blurred vision, photophobia), gastrointestinal discomfort, fatigue, mood swings, and acne. Rare but serious potential side effects include thromboembolic events (deep vein thrombosis, pulmonary embolism), significant visual changes, severe allergic reactions, and psychiatric effects including depression and suicidal ideation. Most side effects are mild to moderate in severity and often diminish with continued treatment. Patients should report any persistent or severe symptoms to their healthcare provider promptly.
Drug interaction
Androxal is primarily metabolized by CYP2D6 and CYP3A4 enzymes, creating potential for interactions with inhibitors or inducers of these pathways. Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine, quinidine) may increase enclomiphene levels, while inducers (e.g., rifampin, carbamazepine) may decrease efficacy. Similarly, strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase exposure, and inducers (e.g., rifampin, St. John’s wort) may reduce effectiveness. Concurrent use with other hormonal therapies, including testosterone products, aromatase inhibitors, or other SERMs, may lead to unpredictable endocrine effects. Androxal may potentially interact with drugs that affect coagulation, potentially increasing thrombotic risk. A comprehensive medication review should be conducted before initiation.
Missed dose
If a dose of Androxal is missed, it should be taken as soon as possible on the same day. However, if it is接近 the time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one. Consistent daily administration is important for maintaining stable testosterone levels, so patients should be counseled on adherence strategies. If multiple doses are missed, patients should contact their healthcare provider for guidance on resuming therapy, as temporary withdrawal symptoms or return of hypogonadal symptoms may occur.
Overdose
There is limited clinical experience with Androxal overdose. Based on its mechanism and similar compounds, potential effects of significant overdose may include exaggerated pharmacological effects such as visual disturbances, nausea, vomiting, ovarian hyperstimulation-like symptoms (despite male use), and emotional lability. There is no specific antidote for enclomiphene citrate overdose. Management should be supportive and symptomatic, including monitoring of vital signs and appropriate symptomatic treatment. Gastric lavage or activated charcoal may be considered if ingestion was recent. Patients should seek immediate medical attention if overdose is suspected. Dialysis is unlikely to be effective due to high protein binding.
Storage
Androxal tablets should be stored at controlled room temperature, between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). The medication should be kept in its original container, tightly closed, and protected from light and moisture. Tablets should not be stored in bathroom cabinets or other areas prone to humidity fluctuations. Androxal should be kept out of reach of children and pets. Unused medication should be properly disposed of according to local regulations, not flushed down toilets or drains. Expired medication should not be used.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Androxal is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual results may vary, and not all patients will experience the described benefits. The safety and efficacy of Androxal have been established through clinical trials but continue to be monitored in post-marketing surveillance. Patients should discuss their medical history, current medications, and treatment goals with their physician before initiating therapy. This information is not exhaustive, and healthcare providers should consult full prescribing information before prescribing.
Reviews
Clinical studies of Androxal have demonstrated significant increases in testosterone levels while maintaining spermatogenesis. In a randomized, double-blind, active-controlled study, 73% of men treated with Androxal 12.5 mg daily achieved average testosterone levels within the eugonadal range, compared to 77% with the 25 mg dose. Semen parameters were preserved or improved in most patients, contrasting with testosterone gel which typically suppresses spermatogenesis. Patients reported improvements in hypogonadal symptoms including energy, libido, and mood. The most comprehensive trial (NCT01993225) showed sustained efficacy over 12 months of treatment with a favorable safety profile. Real-world evidence continues to accumulate, supporting its role as a valuable option for men with secondary hypogonadism who wish to preserve fertility.